Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Singhal, Seema, Mehta, Jayesh, Desikan, Raman, Ayers, Dan, Roberson, Paula, Eddlemon, Paul, Munshi, Nikhil, Anaissie, Elias +6 more·1999·New England Journal of Medicine
DOI 10.1056/nejm199911183412102

Cited by (1,002)

Items 701–800 of 1,002

  1. The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia
    Tait D. Shanafelt, Neil E. Kay · 2006 · Seminars in Oncology
  2. The evolving role of lenalidomide in the treatment of hematologic malignancies
    Efstathios Kastritis, Meletios Athanasios Dimopoulos · 2007 · Expert Opinion on Pharmacotherapy
  3. Adjuvant Therapy for Renal Cell Carcinoma
    Kenneth M. Jacobsohn, C WOOD · 2006 · Seminars in Oncology
  4. Identification of the Genes Involved in Enhanced Fenretinide-Induced Apoptosis by Parthenolide in Human Hepatoma Cells
    Jeong-Hyang Park, Lan Liu, In-Hee Kim, Jong-Hyun Kim, Kyung-Ran You, Dae‐Ghon Kim · 2005 · Cancer Research
  5. Treatment of Relapsed/Refractory Multiple Myeloma
    Efstathios Kastritis, Antonio Palumbo, Meletios Athanasios Dimopoulos · 2009 · Seminars in Hematology
  6. α-Fluoro-substituted thalidomide analogues
    Hon‐Wah Man, Laura G. Corral, David Stirling, George W. Muller · 2003 · Bioorganic & Medicinal Chemistry Letters
  7. Effect of thalidomide in patients with chronic heart failure
    Lars Lysgaard Gullestad, Anne Grete Semb, Even Holt, Rita Skårdal, Thor Ueland, Arne Yndestad, Stig Sophus Frøland, Pål Aukrust · 2002 · American Heart Journal
  8. General aspects of anti-angiogenesis and cancer therapy
    Theresa G. Zogakis, Steven K. Libutti · 2001 · Expert Opinion on Biological Therapy
  9. A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
    Henry Miles Prince, Linda Mileshkin, Andrew Warwick Roberts, Vinod Ganju, Craig R. Underhill, John Vincent Catalano, Richard H. Bell, John Francis Seymour, David Westerman, Paul J. Simmons et al. · 2005 · Clinical Cancer Research
  10. 5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis
    Douglas K. Price, Yukio Ando, Erwin A. Kruger, Michael Weiß, William Douglas Figg · 2002 · Therapeutic Drug Monitoring
  11. Thalidomide in agnogenic and secondary myelofibrosis
    Letizia Canepa, Filippo Ballerini, Riccardo Varaldo, Sabrina Quintino, Lizia Reni, Marino Clavio, Maurizio Miglino, Ivana Pierri, Marco Gobbi · 2001 · British Journal of Haematology
  12. Unexpected Toxicity of Combination Thalidomide and Interferon Alfa-2a Treatment in Metastatic Renal Cell Carcinoma
    Paul Nathan, Martin Eric Gore, Tim G Eisen · 2002 · Journal of Clinical Oncology
  13. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial
    Jiangming Chen, Weijian Zhu, Jie Liu, Guizhen Wang, Xiaoqin Chen, Yun Tan, Weiwei Xu, Li-Wei Qu, Jinyan Li, Huan-Ju Yang et al. · 2021 · Signal Transduction and Targeted Therapy
  14. NLRP3 inflammasome-induced pyroptosis in digestive system tumors
    Jiexia Wen, Bin Xuan, Yang Liu, Liwei Wang, Li He, Xiangcai Meng, Tao Zhou, Yimin Wang · 2023 · Frontiers in Immunology
  15. Drug Repurposing: A Leading Strategy for New Threats and Targets
    Ashish Sriram Mishra, Manimaran Vasanthan, Sivakumar Ponnurengam Malliappan · 2024 · ACS Pharmacology & Translational Science
  16. Medical management of metastatic medullary thyroid cancer
    Jessica E. Maxwell, Scott K. Sherman, Thomas M. O’Dorisio, James R. Howe · 2014 · Cancer
  17. Hematologic malignancies and thrombosis
    Francesca Elice, Francesco Rodeghiero · 2011 · Thrombosis Research
  18. Small Compound 6-O-Angeloylplenolin Induces Mitotic Arrest and Exhibits Therapeutic Potentials in Multiple Myeloma
    Ying Min Liu, Xiao-qin Chen, Heng-Xing Liang, Feng-xiang Zhang, Bo Zhang, Jie Jin, Yonglong Chen, Yong-Xian Cheng, Guang‐Biao Zhou · 2011 · PLoS ONE
  19. α‐fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma
    Li‐Tzong Chen, Tina Liu, Yee Chao, Her Shyong Shiah, Jen‐Yea Chang, Shin‐Hun Juang, S.‐C. CHEN, T.‐R. CHUANG, Y.‐H. CHIN, Jacqueline Whang‐Peng · 2005 · Alimentary Pharmacology & Therapeutics
  20. Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
    Michael Medinger, Natalie Fischer, Alexandar Tzankov · 2010 · Journal of Oncology
  21. Relapsed Multiple Myeloma
    Sagar Lonial · 2010 · Hematology
  22. Targeting inflammatory pathways in chronic lymphocytic leukemia
    Uri Rozovski, Michael J. Keating, Zeev E. Estrov · 2013 · Critical Reviews in Oncology/Hematology
  23. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
    Holkova, Beata, Zingone, Adriana, Kmieciak, Maciej, Bose, Prithviraj, Badros, Ashraf Z., Voorhees, Peter M., Baz, Rachid, Korde, Neha, Lin, Hui-Yi, Chen, Jin-Qiu et al. · 2016 · Clinical Cancer Research
  24. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
    Paola E. Neri, Nizar Jacques Bahlis, Sagar Lonial · 2016 · Clinical Cancer Research
  25. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
    Mateusz Maciejewski, Eugen Lounkine, Steven Whitebread, Pierre J. Farmer, William DuMouchel, Brian K. Shoichet, László Urbán · 2017 · eLife
  26. Thalidomide-derived immunomodulatory drugs as therapeutic agents
    Christine Galustian, Marie‐Christine Labarthe, J. Blake Bartlett, Angus George Dalgleish · 2004 · Expert Opinion on Biological Therapy
  27. Multiple Myeloma: An Old Disease with New Hope for the Future
    A. A. Zaidi, David H. Vesole · 2001 · CA A Cancer Journal for Clinicians
  28. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease
    S Kulkarni, R Powles, Bhawna Sirohi, J. G. Treleaven, Radovan M. Saso, Clive Horton, Ayad Atra, Miguel Ortín, Charles M. Rudin, Sagun D. Goyal et al. · 2003 · Bone Marrow Transplantation
  29. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
    Monica M Mita, Eric Keith Rowinsky, Leonardo Forero, S. Gail Eckhart, Elżbieta Izbicka, Geoffrey R. Weiss, Muralidhar Beeram, Alain C. Mita, Johann Sebastian De Bono, Anthony W. Tolcher et al. · 2006 · Cancer Chemotherapy and Pharmacology
  30. Use of Melphalan, Thalidomide, and Dexamethasone in Treatment of Refractory and Relapsed Multiple Myeloma
    Gordan Srkalović, Paul J. Elson, Beth Trebisky, Mary Ann Karam, Mohamad A. Hussein · 2002 · Medical Oncology
  31. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma
    Brett T. Brinker, Edmund K. Waller, Traci L. Leong, Leonard T. Heffner, Istvan Redei, Amelia A. Langston, Sagar Lonial · 2006 · Cancer
  32. A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma
    David R. Minor, Dana Monroe, Lisa A. Damico, Gloria Meng, Uma Suryadevara, Laurence Elias · 2002 · Investigational New Drugs
  33. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
    Athanasios Zomas, Nicolaos Anagnostopoulos, Meletios Athanasios Dimopoulos · 2000 · Bone Marrow Transplantation
  34. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids
    Kathleen M. Fairfield, Susan E. Hankinson, BERNARD A. ROSNER, David J. Hunter, Graham A. Colditz, Walter Churchill Willett · 2001 · Cancer
  35. Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
    Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2005 · Journal of Clinical Oncology
  36. The Thalidomide-Binding Domain of Cereblon Defines the CULT Domain Family and Is a New Member of the β-Tent Fold
    Andrei N. Lupas, Hongbo Zhu, Mateusz Koryciński · 2015 · PLoS Computational Biology
  37. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia
    Krzysztof Giannopoulos, Anna Dmoszyńska, Małgorzata Kowal, Ewa Wąsik‐Szczepanek, Agnieszka A. Bojarska-Junak, Jacek Roliński, Hartmut Döhner, Stephan Stilgenbauer, Lars Bullinger · 2009 · Leukemia
  38. Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
    Donna M. Weber, Thorsten T. Graef, Mohamad A. Hussein, Ronald M. Sobecks, Gary John Schiller, Lisa C. Lupinacci, James S. Hardwick, Sundar Jagannath · 2012 · Clinical Lymphoma Myeloma & Leukemia
  39. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
    Salvia Sanjay Jain, Catherine Diefenbach, Jasmine M. Zain, O’Connor · 2011 · Core evidence
  40. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Mohamed A. Kharfan‐Dabaja, Mehdi Hamadani, Tea Reljic, Taiga Nishihori, William Bensinger, Benjamin Djulbegović, Ambuj Kumar · 2013 · Journal of Hematology & Oncology
  41. Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
    Nancy A. Brandenburg, Robert Bwire, John Freeman, Florence Houn, Paul Sheehan, Jerome B. Zeldis · 2017 · Drug Safety
  42. Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target
    Saiful Islam, Shudong Wang, Nikola A. Bowden, Jennifer H. Martin, Richard J. Head · 2021 · British Journal of Clinical Pharmacology
  43. Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments
    Caroline L. Alvares, Faith E. Davies, Clive Horton, Gita Wasan Patel, R Powles, Bhawna Sirohi, Roslin Zuha, Alex Gatt, Radovan M. Saso, Jennifer G. Treleaven et al. · 2005 · British Journal of Haematology
  44. Angiogenesis inhibitors in the treatment of cancer
    Jay Rhee, Paulo M. Hoff · 2005 · Expert Opinion on Pharmacotherapy
  45. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome
    Srđan Verstovšek, Hagop M. Kantarjian, Elihu H. Estey, A. Aguayo, Francis Joseph Giles, Taghi Manshouri, Charles Asa Koller, Zeev E. Estrov, Emil J. Freireich, Michael J. Keating et al. · 2001 · Leukemia
  46. Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
    Kozo Yasui, Norimoto Kobayashi, Takashi Yamazaki, Kazunaga Agematsu · 2005 · Current Pharmaceutical Design
  47. Targeted therapy for multiple myeloma
    Kenneth Carl Anderson · 2001 · Seminars in Hematology
  48. Cost‐effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease
    James Rast Stallworth, Jeanette M. Jerrell, Avnish Tripathi · 2010 · American Journal of Hematology
  49. Thalidomide in patients with multiple myeloma and renal failure
    Fádi Fakhouri, Houda Guerraoui, Claire Presne, Julie Peltier, Richard Delarue, Patrice Muret, Bertrand Knebelmann · 2004 · British Journal of Haematology
  50. Immunomodulatory drugs in multiple myeloma
    Swati Andhavarapu, Vivek Roy · 2013 · Expert Review of Hematology
  51. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum β2-microglobulin levels in patients with multiple myeloma
    Orhan Sezer, Kathrin Niemöller, Christian Jakob, Ivana Zavrski, Ulrike Heider, Jan Eucker, O. W. KAUFMANN, K. Possinger · 2001 · Annals of Hematology
  52. Blood Flow Changes in Hepatocellular Carcinoma After the Administration of Thalidomide Assessed by Reperfusion Kinetics During Microbubble Infusion
    Michele Bertolotto, Gabriele Pozzato, Lory Saveria Crocè, Fabiana Nascimben, Cristiana Gasparini, Maria Assunta Cova, Claudio Tiribelli · 2005 · Investigative Radiology
  53. Antiangiogenic strategies in neuroblastoma
    Doménico Ribatti, Mirco Ponzoni · 2004 · Cancer Treatment Reviews
  54. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
    Meletios Athanasios Dimopoulos, Athanasios Anagnostopoulos, Evangelos Terpos, Panagiotis Repoussis, Athanasios Zomas, Eirini Katodritou, Marie Christine Kyrtsonis, Souzana Delibasi, Amalia Vassou, Anastasia G. Pouli et al. · 2006 · PubMed
  55. Clinical impact of novel treatment strategies
    Giuseppe Giaccone · 2002 · Oncogene
  56. Thalidomide: a remarkable comeback
    Jeffrey M. Jacobson · 2000 · Expert Opinion on Pharmacotherapy
  57. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma
    Philipp Schütt, Peter Robert Ebeling, Ulrike Buttkereit, Dieter Brandhorst, Bertram Opalka, Mathias Hoiczyk, Michael Flaßhove, J. Hense, Peter Bojko, Klaus Alfred Metz et al. · 2004 · European Journal Of Haematology
  58. Thalidomide in patients with advanced multiple myeloma
    Ibrahim Yakoub‐Agha, Philippe Moreau, Serge Leyvraz, Christian Berthou, Catherine Payen, Charles Dumontet, Bernard Grosbois, Photis Beris, Corinne Duguet, Michel Attal et al. · 2000 · The Hematology Journal
  59. Routes to molecular glue degrader discovery
    Yanfen Liu, Jieyun Bai, Dong Li, Yong Cang · 2025 · Trends in Biochemical Sciences
  60. Outcomes of primary refractory multiple myeloma and the impact of novel therapies
    Neil Majithia, S. Vincent Rajkumar, Martha Q. Lacy, Francis K. Buadi, Angela A. Dispenzieri, Morie Abraham Gertz, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Yi L. Hwa et al. · 2015 · American Journal of Hematology
  61. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
    Pieter Sonneveld, Edwin de Wit, Philippe Moreau · 2017 · Critical Reviews in Oncology/Hematology
  62. Game of Bones: How Myeloma Manipulates Its Microenvironment
    Tyler Moser-Katz, Nisha S. Joseph, Madhav V. Dhodapkar, Kelvin P. Lee, Lawrence Boise · 2021 · Frontiers in Oncology
  63. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide
    Ahmet Doǧan, L. Ngu, S H Ng, Paul L Cervi · 2005 · Leukemia
  64. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
    Hartmut Goldschmidt, Pieter Sonneveld, F. W. Cremer, Bronno van der Holt, Petra H.M. Westveer, Iris Breitkreutz, Axel Benner, Axel G. Glasmacher, Ingo G.H. Schmidt‐Wolf, Hans Martin et al. · 2003 · Annals of Hematology
  65. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma
    Michael G. Alexandrakis, Freda H. Passam, Constantina Dambaki, Constantina A. Pappa, E. Stathopoulos · 2004 · Journal of Clinical Pathology
  66. The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myeloma
    Tiffany T. Khong, J. Sharkey, A. Spencer · 2008 · Haematologica
  67. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis
    Ping Wu, Faith E. Davies, Clive Horton, Matthew W. Jenner, Biju Krishnan, Caroline L. Alvares, Radovan M. Saso, Rita Mccormack, Sharon Dines, Jennifer G. Treleaven et al. · 2006 · Leukemia & lymphoma/Leukemia and lymphoma
  68. Angiogenesis and antiangiogenic approaches to sarcomas
    John Victor Heymach · 2001 · Current Opinion in Oncology
  69. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
    Martin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, Nina Gulbrandsen, Erik C. Holmberg, Per Trøllund Pedersen, Niels Frost Andersen, Björn Andréasson, Rolf Billström, Kristina Elisabet Carlson et al. · 2012 · European Journal Of Haematology
  70. First thalidomide clinical trial in multiple myeloma: a decade
    Frits van Rhee, Madhav V. Dhodapkar, John D. Shaughnessy, Elias J. Anaissie, David Samuel DiCapua Siegel, Antje Hoering, Jerome B. Zeldis, Bonnie Jenkins, Seema Singhal, Jayesh Mehta et al. · 2008 · Blood
  71. A Mental Retardation-linked Nonsense Mutation in Cereblon Is Rescued by Proteasome Inhibition
    Guoqiang Xu, Xiaogang Jiang, Samie R. Jaffrey · 2013 · Journal of Biological Chemistry
  72. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study
    Donald Scott McMeekin, Michael W. Sill, Kathleen M. Darcy, Deborah J. Stearns-Kurosawa, Kenneth D. Webster, Steven E. Waggoner, Doris M. Benbrook · 2007 · Gynecologic Oncology
  73. Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non–Small Cell Lung Cancer
    David R. Gandara, Samir Narayan, Primo N. Lara, Zelanna Goldberg, Angela M. Davies, Derrick H. M. Lau, Philip C. Mack, Paul H. Gumerlock, Srinivasan Vijayakumar · 2005 · Clinical Cancer Research
  74. When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
    Shardule P. Shah, Sagar Lonial, Lawrence Boise · 2015 · Molecular Cancer Research
  75. Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma
    Anna Mansour, Abdelilah Wakkach, Claudine Blin‐Wakkach · 2017 · Frontiers in Immunology
  76. Old drugs, new uses: Drug repurposing in hematological malignancies
    Vijay Pralhad Kale, Hasan Habib, Robert J. Chitren, Milan Patel, Kartick Chandra Pramanik, Subash C. Jonnalagadda, Kishore B. Challagundla, Manoj Kumar Pandey · 2020 · Seminars in Cancer Biology
  77. The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
    Bingbing Hao, Xiaojing Li, Xinglong Jia, Yuxing Wang, Linhui Zhai, Duanzhuo Li, Jie Liu, Die Zhang, Yu-Lu Chen, Yonghu Xu et al. · 2020 · Acta Pharmacologica Sinica
  78. Immunotherapy in Multiple Myeloma
    Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Sanjay De Mel, Wee Joo Chng · 2020 · Cells
  79. Thalidomide: from tragedy to promise
    R Stolz · 2003 · Swiss Medical Weekly
  80. Thalidomide in solid tumours: the resurrection of an old drug
    Stefan Sleijfer, Wim H.J. Kruit, G. Stoter · 2004 · European Journal of Cancer
  81. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
    Evangelos Terpos, Kanellias, Christoulas, Efstathios Kastritis, Meletios Athanasios Dimopoulos · 2013 · OncoTargets and Therapy
  82. Treatment of plasma cell dyscrasias with lenalidomide
    Meletios Athanasios Dimopoulos, Efstathios Kastritis, S. Vincent Rajkumar · 2008 · Leukemia
  83. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy
    Orhan Sezer, Kathrin Niemöller, O. W. KAUFMANN, Jan Eucker, Christian Jakob, Ivana Zavrski, K. Possinger · 2001 · European Journal Of Haematology
  84. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma
    Francesco Bertolini, Lisa Fusetti, Cristina Rabascio, Saverio Cinieri, Giovanni Martinelli, Giancarlo Pruneri · 2000 · Leukemia
  85. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jörge E. Cortes, Hagop M. Kantarjian, Maher X. Albitar, Deborah Ann Thomas, Stefan H Faderl, Charles Asa Koller, Guillermo Garcia‐Manero, Francis Joseph Giles, Michael Andreeff, Susan Mary O'Brien et al. · 2003 · Cancer
  86. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk
    Liang Yu, Ruidan Su, Bingbo Wang, Long Zhang, Yapeng Zou, Jing Zhang, Lin Gao · 2016 · IEEE Transactions on Computational Biology and Bioinformatics
  87. How I treat elderly patients with myeloma
    Jayesh Mehta, Michèle Cavo, Seema Singhal · 2010 · Blood
  88. Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis
    Jasmin Roya Agarwal, William H. Matsui · 2010 · Anti-Cancer Agents in Medicinal Chemistry
  89. Mirror‐Image Organometallic Osmium Arene Iminopyridine Halido Complexes Exhibit Similar Potent Anticancer Activity
    Ying Fu, Rina Soni, María J. Romero, Ana M. Pizarro, Luca Salassa, Guy J. Clarkson, Jessica M. Hearn, Abraha Habtemariam, Martin Wills, Peter John Sadler · 2013 · Chemistry - A European Journal
  90. Pomalidomide: First Global Approval
    Shelley Elkinson, Paul L. McCormack · 2013 · Drugs
  91. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice
    Cristina Maria de Souza, Luciana Fonseca de Carvalho, Tamara da Silva Vieira, Ana Cândida Araújo e Silva, Míriam Teresa Paz Lopes, Mônica Alves Neves Diniz Ferreira, Sílvia Passos Andrade, Geovanni Dantas Cassali · 2012 · Biomedicine & Pharmacotherapy
  92. Immunomodulatory Drugs
    Edward Crane, Alan F. List · 2005 · Cancer Investigation
  93. Negligible Clinical Effects of Thalidomide in Patients with Myelofibrosis with Myeloid Metaplasia
    Mats Merup, Jack Kutti, G. Birgergård, Nils Mauritzson, Magnus Björkholm, Berit Markevärn, C. Malm, Jan Westin, Jan E.W. Palmblad, Jan Samuelsson · 2002 · Medical Oncology
  94. Perspectives for combination therapy to overcome drug-resistant multiple myeloma
    Laurence P. Catley, Y TAI, D CHAUHAN, Kenneth Carl Anderson · 2005 · Drug Resistance Updates
  95. Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma
    Sachin R. Shah, Thu M Tran · 2007 · Drugs
  96. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients
    Kristen Nooshin Ganjoo, Annette M. Moore, Attilio Orazi, Joy A. Sen, Cynthia S. Johnson, Caroline An · 2007 · Journal of Cancer Research and Clinical Oncology
  97. Novel anti-myeloma agents and angiogenesis
    Konstantinos Anargyrou, Meletios Athanasios Dimopoulos, Orhan Sezer, Evangelos Terpos · 2008 · Leukemia & lymphoma/Leukemia and lymphoma
  98. Immunotherapy in multiple myeloma – possibility or probability?
    S. J. Harrison, Gordon Cook · 2005 · British Journal of Haematology
  99. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    Antonio Pierangelo Palumbo, Alessandra Larocca, P. Falco, Grazia Sanpaolo, Antonietta Pia Falcone, V Federico, Letizia Canepa, Monica Crugnola, Maurizio Genuardi, Valeria Magarotto et al. · 2010 · Leukemia
  100. Role of tumour angiogenesis in haematological malignancies
    Michael Medinger, Jakob Robert Passweg · 2014 · Swiss Medical Weekly